The AMR Action Fund aims to bring 2-4 new antibiotics to patients by 2030. We will work with partners to create market conditions that enable sustainable investment in the antibiotic pipeline.
The AMR Action Fund expects to invest more than US$1 billion in smaller biotech companies and provide industry expertise to support the clinical development of novel antibiotics
Strengthens and accelerates the research and development of antibiotics through investment and provision of industry resources and expertise to biotechnology companies.
Brings together a broad alliance of industry and non-industry stakeholders, including philanthropies, development banks, and multilaterals, to encourage governments to create market conditions that enable sustainable investment in the pipeline.
Our CEO, Dr. Henry Skinner, joins the Fund from Tekla Capital Management, where he was Senior Vice President, Venture. Prior to joining Tekla, Dr. Skinner Served as Deputy Head and Managing Director of Novartis Venture Fund. In addition, Dr. Skinner has been CEO of SelectX Pharmaceuticals and NeoGenesis Pharmaceuticals and has held positions in Business Development for Novartis Institutes for Biomedical Research, Pfizer, Pharmacia, Pharmacia & Upjohn and Lexicon Genetics. Dr. Skinner was a postdoctoral fellow at Baylor College of Medicine in the department of Human and Molecular Genetics, earned his Ph.D. in Microbiology and M.S. in Biochemistry from the University of Illinois and M.S. and B.S. in Biology/Biotechnology from Worcester Polytechnic Institute.
Chief Investment Officer
Board Chair Bill Burns has held numerous leadership positions in the pharmaceutical industry throughout his career, including serving as CEO of the global Pharmaceutical Division of Roche. He has also served on the main boards of Roche, Genentech, Chugai, and as Lead non-executive director of Shire Pharmaceuticals and the smaller biotechnology companies Crucell, Biotie and Okairos. He is currently Chair of Molecular Partners and Vestergaard, and he is Vice Chair of Mesoblast. Additionally, Mr. Burns is a member of the Scientific Advisory Board of the Center for Integrated Oncology of the University of Cologne/Bonn and on the Board of Trustees to the Institute of Cancer Research in London. He previously served on the Wellcome Trust Board of Governors.
Head of Finance and Operations
Head of External Affairs
Carly joined the AMR Action Fund as an analyst in November 2021. She received her MS in cell biology and PhD in microbiology at Rutgers University. During her doctoral and post-doctoral research, she developed and evaluated a novel anti-tubercular drug candidate. Additionally, she used a multi-omics approach to characterize the physiology of drug-tolerant Mycobacterium tuberculosis isolates. Carly's scientific work has led to several publications and recognition through various awards.
Director of International Policy
Deepali Patel joins the AMR Action Fund with over 15 years of experience in global health policy in the US, Europe, Central America, and Asia. Prior to the Fund, she served for seven years as a Senior Policy Officer at Gavi, the Vaccine Alliance, where she led the development of policies and strategies to accelerate the development, distribution, and uptake of high-impact vaccines in low- and middle-income countries. Most recently she oversaw the successful approval of Gavi's $2 billion malaria vaccine investment. She previously spent nine years at the National Academy of Medicine in the US, developing health policy and research recommendations for US and global stakeholders. She is a 2009 Fulbright Scholar, a graduate of the 2017 Advanced Course in Vaccinology, and received her BS in Foreign Service from Georgetown University and her MPH from Johns Hopkins School of Public Health.
Communications Director Chris Sweeney joins us from the Harvard T.H. Chan School of Public Health, where he held several positions, including senior media relations manager and features editor. Prior to that, Chris worked on the communications team at Partners In Health, where he primarily focused on infectious disease programs in Lesotho, Malawi, Rwanda, and Russia. Chris has also had a successful career as a magazine writer whose work has appeared in national and international publications and has also won numerous journalism awards.
He holds an MSJ from Northwestern University’s Medill School and a BA from UMass Amherst.
Director, U.S. Policy
Jaclyn Levy joins the Fund from the Infectious Diseases Society of America (IDSA), where she served as Director of Public Policy and advanced a broad portfolio of science and public health policy issues. Prior to IDSA, Jaclyn worked as a biosecurity analyst for the U.S. Department of Homeland Security and as a scientific editor and consultant. She has over a decade of experience in federal and global policy and advocacy work and has authored numerous publications on pandemic preparedness, antimicrobial resistance, molecular diagnostics, and biomedical R&D.
Jaclyn holds a BA from The George Washington University and an MS in Biohazardous Threat Agents & Emerging Infectious Diseases from Georgetown University. She was selected as a 2020 Atlantic Council Millennium Fellow.
The pharmaceutical industry and leading global philanthropies and development banks are stepping up to take on the challenge of AMR
Antimicrobial resistance (AMR) poses a growing threat to public health and to the viability of health systems around the world. We need only look at the devastating impact of the COVID-19 crisis to know that now is the time to begin a global effort to combat AMR. While Lilly is not directly engaged in antimicrobial antibiotic research and development, we are supporting the AMR Action Fund to help address the challenges in bringing new antibiotics to market. The industry is doing its part to help bridge the gap in AMR research and development in the short-term, but we need policymakers to take action now to create a viable market that incentivizes future research in this crucial area.
Governments and experts have been talking about the need to tackle the public health crisis of AMR for years. But so far no action has followed the talk. Meanwhile biotech companies developing much needed new antibiotics go bankrupt because the costs of late stage R&D cannot be recouped later in sales.
Biopharmaceutical companies want to help break the gridlock and respond to this clear public health need.
In setting up the AMR Action Fund, IFPMA is proud to have benefited from collaboration with the World Health Organization, the European Investment Bank, and the Wellcome Trust.
The Fund provides a bridging solution to help biotech companies take their discoveries over the finishing line. To recreate a viable innovation ecosystem for antibiotic research, we need governments to step up too. We need reforms that acknowledge the huge value that new antibiotics bring to society and safeguard our future from the global threat of AMR.
AMR is called a “silent tsunami,” and failing to put in a place a robust plan of action to combat this global threat could result in a greater impact to humanity than the COVID-19 pandemic. Under such circumstances, it is extremely important to launch the AMR Action Fund now. SHIONOGI hopes that this Fund will help to deliver AMR therapeutics quickly and continuously to more patients by creating a new global ecosystem in the antibacterial space.
Daiichi Sankyo is keenly aware of both the threat of AMR and the importance of effective antibiotics. In recent years, the creation of new antibiotics has been challenging and characterized by low marketability, which makes it difficult for pharmaceutical companies to carry out research and development activities and reach the commercialization stage.
The AMR Action Fund will gather accumulated industry knowledge of antibiotics development and help rectify this situation. Investments in the Fund will work to accelerate the development of effective antibiotics continuously and go a long way to eventually overcoming the global AMR problem.
At Boehringer Ingelheim, we are driven by the desire to improve the life of patients. We focus our innovation to where the medical needs are the highest. We believe that the increasing threat posed by drug-resistant bacteria and fungi is one of the key areas to be addressed in advancing human health globally. At the same time, we are convinced that a broad knowledge coalition will enhance the likelihood of success. This is why we join forces with other industry partners in the new AMR Action Fund to actively contribute to researching, developing and making available much needed new treatment options to combat infectious disease.
Antimicrobial resistance (AMR) represents a global public health crisis. Novel antibiotics are urgently needed to tackle this problem. However, research and development of new antibiotics is challenging, for various scientific, regulatory and economic reasons. Roche is proud to be a partner in the AMR action fund, which addresses the existing funding gap for clinical development of new antibiotics leading up to commercialization. Together with the efforts of policymakers to implement market-based reforms, the AMR action fund will make a major contribution toward the development of a sustainable antibiotics market and ecosystem for the benefit of patients worldwide.